Takeda Pharmaceutical Co Ltd (TAK) CEO Christophe Weber on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/05/21
Takeda FY2020 Q3 Results Demonstrate Growth Acceleration and Continued Resilience; Full-Year Management Guidance for FY2020 Confirmed, Forecast Raised for Free Cash Flow and Reported EPSBusiness Wire • 02/04/21
Data at EAHAD 2021 Highlight Value of Takeda's Leading Hematology Portfolio in Clinical Settings and Commitment to Patient-Focused AdvancementsBusiness Wire • 02/03/21
Takeda Presents Positive Results For Mobocertinib in Patients with EGFR Exon20 insertion+ mNSCLC Who Received Prior Platinum-based ChemotherapyBusiness Wire • 01/28/21
Takeda's Entyvio SC and Celltrion's Remsima SC EU5 Launches Have Benefitted from Parent Brand Reputation, New Clinical Data, and COVID-19 Restraints, According to Spherix Global InsightsPRNewsWire • 01/20/21
Takeda Provides Pipeline Update and Shares Goal to Increase Revenue 50% by FY2030 at the 39th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/11/21
Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USDBusiness Wire • 12/21/20
U.S. FDA Approves Supplemental New Drug Application for Takeda's ICLUSIG® (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CMLBusiness Wire • 12/18/20
U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda's TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic EsophagitisBusiness Wire • 12/15/20
Takeda's Pipeline Has Potential to Contribute Significantly to Revenue Growth Over Next DecadeBusiness Wire • 12/09/20
Takeda Announces Approval of TAKHZYRO® (lanadelumab) subcutaneous injection in China for the Treatment of Hereditary AngioedemaBusiness Wire • 12/08/20
Takeda Presents Real-World Evidence at ASH 2020, Demonstrating Its Long-Standing Commitment to Personalizing Treatments for Rare Bleeding DisordersBusiness Wire • 12/07/20
Takeda Further Enables Hemophilia A Personalized Care With Launch of myPKFiT® Software for ADYNOVATE® [Antihemophilic Factor (Recombinant), PEGylated]Business Wire • 12/02/20
Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company LimitedBusiness Wire • 11/30/20